COMPANY OVERVIEW
Located in Newport Beach, California, Daniel Alain, Inc. is a hair loss biotech and beauty company whose purpose and research efforts are focused on developing innovative solutions for hair loss, hair thinning, and hair shedding in women.
Over 10 years ago, Daniel Alain Hafid, and Dr. Goren began a research partnership funded by Hafid to explore advancements in Minoxidil-based hair loss treatments as well as new solutions to hair shedding.
Looking beyond his success with world-renowned Follea luxury wig and toppers, Hafid desired to pursue first-to-market hair loss solutions for men and women under the Daniel Alain brand – seeking to offer a 360 solution for all stages of hair loss.
Between 2018 and 2022, three novel, patented products were brought to market under the Daniel Alain brand – Intact Anti-Hair Shedding Treatment, Minoxidil Response Test, and SULT1A1 Enzyme Booster – as well as establishing CLIA-certified DA Labs for processing the Minoxidil Response Test and future products.
In addition, Hafid purchased the DermaGenome HairDX portfolio developed by Dr. Goren, thus expanding Daniel Alain, Inc. into genetic diagnostics to screen for Androgenetic Alopecia and Androgen Sensitivity in women.
2023 marks the expansion of Daniel Alain, Inc. into the MD/PRO channel, seeking reseller partnerships with physicians, dermatologists, and hair restoration establishments with the exciting introduction of INTACT Pro, Minoxidil SULT1A1 Rapid Test, and HairDX Genetic Tests.
No other company can help customers from early stages of hair loss to hair regrowth to providing alternative hair solutions with premium wigs and toppers.
Daniel Alain’s innovative portfolio will Improve Patient Care. Improve Patient Outcome.™ to help men and women feel in control of their hair loss and regain confidence to enjoy life to its fullest.
Prof. Dr. Andy Goren
Prof. Dr. Andy Goren has over 20 years of experience in research, development and commercialization of breakthrough therapeutics and diagnostics.
Among the list of many firsts in dermatology, Prof. Goren was the first to develop a clinical genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to develop a clinical acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to develop a rapid test for predicting minoxidil response in androgenetic alopecia.
Prof. Goren is actively involved in the development, commercialization, and listing of several drugs and medical devices including new therapies for female pattern hair loss, chemotherapy induced alopecia, excessive hair shedding, and female sexual dysfunction. His latest research involves the development of dermatology therapies based on genetically modified organisms.
Prof. Goren currently serves as a visiting Professor at the Department of Dermatology and Venereology, Clinical Hospital Center Sestre Milosrdnice in Zagreb, Croatia; a visiting Medical Doctor at the Department of Dermatology and Venereology, L.T.M. Medical College Sion in Mumbai, India; a Medical Doctor at the Skin & Cosmetic Research Dept. Shanghai Skin Disease Hospital, Shanghai, China; and the Global Medical Director of Hairmore Group in Beijing, China.
Prof. Goren has published dozens of manuscripts in dermatology. He is an honorary as well as ordinary member of several dermatology societies world-wide as well as a regular lecturer at dermatology congresses around the world. He held numerous appearances and interviews on mainstream TV, radio, and prestigious newspapers.
Daniel Hafid, CEO & Founder
Entrepreneurism runs deep within Daniel Alain Hafid, whose father, René, was the renowned Parisian hair stylist and creator of René of Paris Wigs – the epitome of fashionable, synthetic wigs in the 80’s and 90’s.
Working alongside his father for 30 years, Daniel learned the detailed craftsmanship of making extraordinary alternative hair solutions for women.
Daniel launched Follea® International in 2004, setting the highest standard for exclusive 100% European human hair alternative hair solutions. Today, Follea holds the reputation as the epitome of luxury, added hair.
The success of Follea and impact his luxury human hair pieces had on women with alopecia or those affected by hair loss from chemotherapy propelled Daniel’s sense of purpose in a new direction - helping women and men throughout all stages of life attain beautiful hair with an emphasis on hair thinning and hair loss. Daniel invested heavily into research and development in the areas of hair loss diagnosis, treatment response and preventative care.
Today, Daniel is at the helm of Daniel Alain championing hair wellness and hair loss solutions through assiduous research and development projects, bringing first-to-market product innovations. Daniel's passion for beautiful hair and inherent understanding of how hair makes people feel continues to push innovation, artistry, craftsmanship and unmatched quality throughout his portfolio of DA 360 products.
Daniel has touched the lives of many and ardently continues his pursuit to help transform lives by providing exceptional solutions for extraordinary hair no matter what stage of the hair loss journey.